Phaseline

Targets › IRE1

IRE1 (Serine/threonine-protein kinase/endoribonuclease IRE1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Neurology; next expected readout Jan 2028.

Serine/threonine-protein kinase and endoribonuclease that acts as a key sensor for the endoplasmic reticulum unfolded protein response (UPR). In unstressed cells, the endoplasmic reticulum luminal domain is maintained in its inactive monomeric state by binding to the endoplasmic reticulum chaperone HSPA5/BiP. Accumulation of misfolded proteins in the endoplasmic reticulum causes release of HSPA5/BiP, allowing the…. (UniProt, O75460)

Open in Phaseline: the race on IRE1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
The George InstituteDeferoxamine Mesylate
Iron chelator that reduces iron-mediated oxidative stress and secondary brain injury from
IRE1, FTH1Phase 3Intracerebral HemorrhageJan 2028

Conditions

Intracerebral Hemorrhage (1)

Modalities

small molecule (1)

Companies

The George Institute (1)

Related targets

FTH1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.